.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Treatment of Multiple Myeloma in 2017 and Beyond

EP. 1: Classifying Indolent Versus Active Myeloma

January 17th 2017

EP. 2: Treating High-Risk Asymptomatic Myeloma

January 17th 2017

EP. 3: New Data for Newly Diagnosed Myeloma

January 17th 2017

EP. 4: Which Proteasome Inhibitor for Upfront Treatment of Myeloma?

January 17th 2017

EP. 5: Transplant in Multiple Myeloma

January 17th 2017

EP. 6: Consolidation/Maintenance Therapy in Myeloma

January 17th 2017

EP. 7: Elderly Patients With Myeloma

January 17th 2017

EP. 8: Relapsed/Refractory Myeloma: Daratumumab-Containing Triplets

January 17th 2017

EP. 9: Choosing Triplet Therapy at Myeloma Relapse

January 17th 2017

EP. 10: Emerging Therapies for Myeloma

January 17th 2017

EP. 11: Immunotherapy for Myeloma & Final Thoughts on Myeloma Research at ASH 2016

January 17th 2017